1. Medtech Insight
  2. >>Device Area
  3. >>Respiratory

New-Gen Devices Offer Sleep Apnea Patients Alternative CPAP Routes

 
• By Jenny Blair

With half or more of all diagnosed obstructive sleep apnea patients who need continuous positive airway pressure machines unwilling or unable to use these devices, there’s a large unmet need for an alternative treatment. Startups are rising to the challenge with neuromodulation platforms, a mouthguard-like suction device, a nasal device with microblowers, and a vibrating device that nudges patients to turn on their sides.

Sleep Disorder
• Source: shutterstock.com

Obstructive sleep apnea (OSA) is a common, devastating and costly condition. It affects an estimated 100 million people worldwide, of whom 18 million are in the US alone, and its societal costs are huge. A 2010 joint Harvard Medical School-McKinsey & Company report estimated that the annual cost of moderate to severe OSA in the US is between $65bn- $165bn, including diagnosis and treatment, hidden health-care costs (notably cardiovascular disease, with which moderate to severe OSA is strongly associated), traffic and workplace accidents, and absenteeism.

For decades, the go-to treatment for moderate to severe sleep apnea has been for the patient to wear a continuous...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Respiratory

Anglonordic 25: Pictura Bio’s One-Minute Pathogen-Identifying Diagnostic Test

 
• By Natasha Barrow

“Infectious disease should be treated in the community, not in hospitals,” Alex Batchelor, Pictura Bio CEO, told Medtech Insight at the Anglonordic Life Science Conference on 3 April in London.

LSI 2025: Intuitive Surgical CEO Gary Guthart On da Vinci 5’s Force Feedback, Digital Coaching, ION Expansion, And Robotic Surgery’s Future

 
• By Marion Webb

Medtech Insight sat down with Intuitive Surgical CEO Gary Guthart at the recent LSI USA conference to discuss the full launch of the new da Vinci 5 robotic system and planned digital enhancements. Guthart also offered his views on health care interoperability, AI regulation, outpatient surgeries, autonomous robots, and how the company is harnessing technology to shape the future of robotic surgery.

Owlstone Medical Develops P.aeruginosa Breath Test For Cystic Fibrosis Patients

 
• By Natasha Barrow

Cambridge, UK-based breath biopsy company Owlstone Medical will apply its volatile organic compound analysis platform in an attempt to develop a test for the identification and monitoring of pseudomonas aeruginosa in patients with cystic fibrosis.

Recall Alerts For Boston Scientific, Philips, J&J, And More

 
• By Elizabeth Orr

The US FDA has announced seven device safety actions in recent days. The most serious, which relates to a manufacturing defect in Boston Scientific’s Accolade pacemaker, has been linked to 832 injuries and two deaths.

More from Device Area

Digital Health Roundup: Synchron Syncs With Apple, Ketryx’s AI Agents, AdvaMed’s AI RoadMap

 
• By Marion Webb, Brian Bossetta, Natasha Barrow, Elizabeth Orr, and Shubham Singh

In this week's Digital Health Roundup, MedTech Insight's Shubham Singh explores how Ketryx's launch of validated AI agents could reshape compliance automation in medtech. Marion Webb highlights news from BCI makers Synchron, Axoft and Subsense. Elizabeth Orr discusses AI advances at the FDA.

Guardant’s Multi-Cancer Detection Test Granted FDA Breakthrough Device Designation

 
• By Natasha Barrow

Guardant Health’s methylation-based blood test – Shield MCD – showed a specificity of 98.6% and sensitivity of 75% across eight cancer types in its clinical validation data presented at ASCO.

GE HealthCare Announces US Launch Of Longer Half-Life PET MPI Agent For Ischemia Detection

 
• By Shubham Singh

GE HealthCare is pursuing a dual-front imaging strategy with its PET MIP agent Flyrcado for detecting artery disease: It lasts longer than current PET scan tracers and allows patients to do treadmill-based stress tests alongside the scan.